$SRZN
Surrozen, Inc./DE

2024 Q4 Form 10-Q Financial Statement

#000095017024122318 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $10.00M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.568M
YoY Change -0.06%
% of Gross Profit
Research & Development $5.200M
YoY Change -14.92%
% of Gross Profit
Depreciation & Amortization $342.0K
YoY Change -28.75%
% of Gross Profit
Operating Expenses $8.768M
YoY Change -21.64%
Operating Profit $1.232M
YoY Change -111.01%
Interest Expense $431.0K
YoY Change -34.7%
% of Operating Profit 34.98%
Other Income/Expense, Net -$3.097M
YoY Change -3831.33%
Pretax Income -$1.434M
YoY Change -86.28%
Income Tax
% Of Pretax Income
Net Earnings -$1.400M
YoY Change -86.54%
Net Earnings / Revenue -14.0%
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$0.44
COMMON SHARES
Basic Shares Outstanding 3.250M 3.206M
Diluted Shares Outstanding 3.228M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.01M
YoY Change -28.6%
Cash & Equivalents $31.00M
Short-Term Investments
Other Short-Term Assets $2.078M
YoY Change -28.34%
Inventory
Prepaid Expenses
Receivables $12.20M
Other Receivables $0.00
Total Short-Term Assets $45.29M
YoY Change -6.35%
LONG-TERM ASSETS
Property, Plant & Equipment $856.0K
YoY Change -65.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $351.0K
YoY Change -6.65%
Total Long-Term Assets $2.712M
YoY Change -51.71%
TOTAL ASSETS
Total Short-Term Assets $45.29M
Total Long-Term Assets $2.712M
Total Assets $48.00M
YoY Change -11.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $276.0K
YoY Change -3.83%
Accrued Expenses $4.317M
YoY Change 9.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.120M
YoY Change -8.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $36.21M
YoY Change 1911.72%
Total Long-Term Liabilities $36.21M
YoY Change 1911.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.120M
Total Long-Term Liabilities $36.21M
Total Liabilities $42.33M
YoY Change 401.43%
SHAREHOLDERS EQUITY
Retained Earnings -$257.2M
YoY Change 20.86%
Common Stock $0.00
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.667M
YoY Change
Total Liabilities & Shareholders Equity $48.00M
YoY Change -11.07%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.400M
YoY Change -86.54%
Depreciation, Depletion And Amortization $342.0K
YoY Change -28.75%
Cash From Operating Activities -$6.752M
YoY Change -33.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K
YoY Change -90.0%
NET CHANGE
Cash From Operating Activities -6.752M
Cash From Investing Activities 0.000
Cash From Financing Activities -1.000K
Net Change In Cash -6.753M
YoY Change 170.12%
FREE CASH FLOW
Cash From Operating Activities -$6.752M
Capital Expenditures $0.00
Free Cash Flow -$6.752M
YoY Change -33.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001824893
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Surrozen, Inc./DE
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39635
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-1374889
dei Entity Address Address Line1
EntityAddressAddressLine1
171 Oyster Point Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
489-9000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3249798
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31012000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36043000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12196000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2152000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2078000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2937000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
45286000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
41132000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
856000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1969000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
817000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1889000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
688000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
688000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
351000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
402000
CY2024Q3 us-gaap Assets
Assets
47998000
CY2023Q4 us-gaap Assets
Assets
46080000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
276000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
525000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4317000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4126000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1527000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2497000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6120000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7148000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
882000
CY2024Q3 srzn Warrant Liability
WarrantLiability
36211000
CY2023Q4 srzn Warrant Liability
WarrantLiability
115000
CY2024Q3 us-gaap Liabilities
Liabilities
42331000
CY2023Q4 us-gaap Liabilities
Liabilities
8145000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3250000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3250000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2063000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2063000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
262887000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
259630000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257220000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221695000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5667000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37935000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47998000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46080000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10000000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10000000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5200000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6112000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15782000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21135000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3568000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3572000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11165000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12209000
CY2024Q3 srzn Restructuring Expenses
RestructuringExpenses
0
CY2023Q3 srzn Restructuring Expenses
RestructuringExpenses
1505000
srzn Restructuring Expenses
RestructuringExpenses
0
srzn Restructuring Expenses
RestructuringExpenses
2712000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
8768000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
11189000
us-gaap Operating Expenses
OperatingExpenses
26947000
us-gaap Operating Expenses
OperatingExpenses
36056000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1232000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11189000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16947000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36056000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
431000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
661000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1306000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1831000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3097000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
83000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
513000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2024Q3 srzn Loss On Issuance Of Common Stock Value And Warrants
LossOnIssuanceOfCommonStockValueAndWarrants
0
CY2023Q3 srzn Loss On Issuance Of Common Stock Value And Warrants
LossOnIssuanceOfCommonStockValueAndWarrants
0
srzn Loss On Issuance Of Common Stock Value And Warrants
LossOnIssuanceOfCommonStockValueAndWarrants
-20397000
srzn Loss On Issuance Of Common Stock Value And Warrants
LossOnIssuanceOfCommonStockValueAndWarrants
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1434000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10445000
us-gaap Net Income Loss
NetIncomeLoss
-35525000
us-gaap Net Income Loss
NetIncomeLoss
-34129000
CY2024Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
242000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1434000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10449000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35525000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33887000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.96
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3228000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3228000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2033000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2033000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2826000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2826000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2012000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2012000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37935000
CY2024Q1 srzn Adjustment To Additional Paid In Capital Reclassification Of Early Exercised Stock Options
AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
1000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1030000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-8830000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
30136000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
42000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1145000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-25261000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
6062000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1039000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-1434000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5667000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76001000
CY2023Q1 srzn Adjustment To Additional Paid In Capital Reclassification Of Early Exercised Stock Options
AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
13000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1129000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
191000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-14297000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
63037000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
187000
CY2023Q2 srzn Adjustment To Additional Paid In Capital Reclassification Of Early Exercised Stock Options
AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
8000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1158000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
55000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-9387000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
55058000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2023Q3 srzn Adjustment To Additional Paid In Capital Reclassification Of Early Exercised Stock Options
AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
6000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
913000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-10445000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
45531000
us-gaap Profit Loss
ProfitLoss
-35525000
us-gaap Profit Loss
ProfitLoss
-34129000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1120000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1460000
us-gaap Share Based Compensation
ShareBasedCompensation
3214000
us-gaap Share Based Compensation
ShareBasedCompensation
3200000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1072000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
937000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-688000
srzn Transaction Costs Allocated To Pre Funded Warrants And Warrants In Connection With The Private Placement
TransactionCostsAllocatedToPreFundedWarrantsAndWarrantsInConnectionWithThePrivatePlacement
1507000
srzn Transaction Costs Allocated To Pre Funded Warrants And Warrants In Connection With The Private Placement
TransactionCostsAllocatedToPreFundedWarrantsAndWarrantsInConnectionWithThePrivatePlacement
0
srzn Loss On Issuance Of Common Stock Pre Funded Warrants And Warrants
LossOnIssuanceOfCommonStockPreFundedWarrantsAndWarrants
20397000
srzn Loss On Issuance Of Common Stock Pre Funded Warrants And Warrants
LossOnIssuanceOfCommonStockPreFundedWarrantsAndWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1851000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-83000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
44000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-859000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-955000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-51000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-38000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-249000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-371000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
192000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2728000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1852000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1643000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21109000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33052000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
398000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28044000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
70665000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42223000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16043000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
srzn Proceeds From Issuance Of Common Stock Upon Employee Stock Plan Purchases
ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases
42000
srzn Proceeds From Issuance Of Common Stock Upon Employee Stock Plan Purchases
ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases
187000
srzn Repurchase Of Early Excercised Stock Options
RepurchaseOfEarlyExcercisedStockOptions
0
srzn Repurchase Of Early Excercised Stock Options
RepurchaseOfEarlyExcercisedStockOptions
55000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16085000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5031000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9306000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36731000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25095000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31700000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34401000
srzn Vesting Of Early Exercises Of Stock Options
VestingOfEarlyExercisesOfStockOptions
1000
srzn Vesting Of Early Exercises Of Stock Options
VestingOfEarlyExercisesOfStockOptions
27000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31012000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33975000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
688000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
426000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
31700000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
34401000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Organization and Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Surrozen, Inc., or the Company, is a clinical stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company, a Delaware corporation, is located in South San Francisco, California and it operates and manages its business in one operating segment. Surrozen Netherlands, B.V. was incorporated in May 2022 and is located in Amsterdam, Netherlands as a wholly-owned subsidiary of the Company.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred net losses since inception. During the three and nine months ended September 30, 2024, the Company incurred a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. For the three and nine months ended September 30, 2023, the Company incurred a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. For the nine months ended September 30, 2024 and 2023, the Company used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash in operations, respectively. As of September 30, 2024, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an accumulated deficit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">257.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company expects operating expenses to continue to be significant in connection with its ongoing clinical study and anticipates the need to raise additional capital to continue to execute its long-range business plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management believes that the existing cash and cash equivalents, plus a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment received in October 2024 (see Note 5),</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are sufficient for the Company to continue operating activities for at least the next 12 months from the date of issuance of its unaudited condensed consolidated financial statements. However, if the Company’s anticipated cash burn is greater than anticipated, the Company could use its capital resources sooner than expected which may result in the need to reduce future planned expenditures and/or raise additional capital to continue to fund the operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 13, 2023, the Company filed a certificate of amendment to its certificate of incorporation to effect a 1-for-15 reverse stock split of the issued and outstanding common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock was converted into one issued and outstanding share of common stock, without any change in par value per share.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Reverse Stock Split affected all shares of common stock outstanding immediately prior to the effectiveness of the Reverse Stock Split, as well as the number of shares of common stock available for issuance under the equity incentive plans and employee stock purchase plan. In addition, the Reverse Stock Split effected a reduction in the number of shares of common stock issuable upon the exercise of stock options, restricted stock units and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split with a corresponding increase in the exercise price per share applicable to such stock options and warrants. No fractional shares were issued because of the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof. All share and per share amounts in these unaudited condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the Reverse Stock Split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1400000
us-gaap Net Income Loss
NetIncomeLoss
-35500000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10400000
us-gaap Net Income Loss
NetIncomeLoss
-34100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33100000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31000000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257200000
CY2024Q4 srzn Milestone Payments
MilestonePayments
10000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On December 13, 2023, the Company filed a certificate of amendment to its certificate of incorporation to effect a 1-for-15 reverse stock split of the issued and outstanding common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock was converted into one issued and outstanding share of common stock, without any change in par value per share.
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">equires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include certain accrued expenses for research and development activities and fair value of warrants issued in connection with the closing of a private placement in April 2024. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash and cash equivalents. The Company’s cash is held by financial institutions that may at times exceed federally insured limits. However, the Company’s exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the unaudited condensed consolidated balance sheets. The Company believes it is not exposed to significant credit risk on cash. The Company’s cash equivalents were held in custodial accounts maintained by third-party custodians. The Company’s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> policy is to invest cash in institutional money market funds with high credit quality to limit the amount of credit exposure. The Company has not experienced any losses on its cash equivalents.</span></p>
us-gaap Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses accounts receivable for credit losses and, to date, no credit losses have been recorded.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a Collaboration and License Agreement, or CLA, with Boehringer Ingelheim International GmbH, or BI, to which the Company licensed certain rights to its intellectual property that is determined within the scope of ASC 606. The terms of the CLA include payments to the Company of a non-refundable upfront payment, development, regulatory and commercial milestone payments and royalties on net sales of licensed products.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the Company’s intellectual property granted to BI represented one performance obligation for the purposes of conducting the partnership research and further development on SZN-413. The transaction price was determined to be the non-refundable upfront payment. Variable consideration related to future milestones is fully constrained because the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded as revenue on a cumulative catch-up basis during the period of adjustment. The Company will recognize sales-based royalties as revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12163000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
806000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q4 srzn Fixed Asset Impairment Loss
FixedAssetImpairmentLoss
200000
CY2024Q3 srzn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
715000
CY2023Q4 srzn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1751000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
632000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
606000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
731000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
580000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2078000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2937000
CY2024Q3 us-gaap Accrued Employee Benefits Current And Noncurrent
AccruedEmployeeBenefitsCurrentAndNoncurrent
2443000
CY2023Q4 us-gaap Accrued Employee Benefits Current And Noncurrent
AccruedEmployeeBenefitsCurrentAndNoncurrent
2508000
CY2024Q3 srzn Accrued Research And Development Expenses Current And Noncurrent
AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent
1626000
CY2023Q4 srzn Accrued Research And Development Expenses Current And Noncurrent
AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent
1261000
CY2024Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
87000
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
65000
CY2024Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
161000
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
292000
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4317000
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4126000
srzn Milestone Payments
MilestonePayments
10000000
CY2023Q1 srzn Reduction In Workforce
ReductionInWorkforce
0.25
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
1200000
CY2024Q1 srzn Reduction In Workforce
ReductionInWorkforce
0.38
us-gaap Other Restructuring Costs
OtherRestructuringCosts
1500000
CY2022Q4 srzn Restructuring Begining Balance
RestructuringBeginingBalance
0
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
1207000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
726000
CY2023Q1 srzn Restructuring Endining Balance
RestructuringEndiningBalance
481000
CY2023Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
457000
CY2023Q2 srzn Restructuring Endining Balance
RestructuringEndiningBalance
24000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
1505000
CY2023Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
1304000
CY2023Q3 srzn Restructuring Endining Balance
RestructuringEndiningBalance
225000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
668000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
891000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1559000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
32000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1527000
CY2024Q2 srzn Equity Financing Shares
EquityFinancingShares
1100000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
40000
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
11100000
CY2024Q2 srzn Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
17500000
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
15.5
CY2024Q2 srzn Pre Funded Warrants Purchase Price
PreFundedWarrantsPurchasePrice
15.4999
CY2024Q2 srzn Fair Value Of Class Of Warrants Issued
FairValueOfClassOfWarrantsIssued
37900000
CY2024Q2 srzn Loss On Issuance Of Common Stock Pre Funded Warrants And Warrants
LossOnIssuanceOfCommonStockPreFundedWarrantsAndWarrants
20400000
CY2024Q2 us-gaap Other Expenses
OtherExpenses
1500000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17082000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5907000
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
172.5
CY2024Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-08-12
srzn Warrant Redemption Condition Minimum Share Price Scenario Two
WarrantRedemptionConditionMinimumSharePriceScenarioTwo
270
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
311000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.7
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M26D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
258000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
9000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
7000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
30.74
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
553000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M10D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
786000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
240000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
25.72
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y1M28D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
224000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
7.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
9.47
CY2024Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1039000
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
913000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3214000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3200000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y25D
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-122318-index-headers.html Edgar Link pending
0000950170-24-122318-index.html Edgar Link pending
0000950170-24-122318.txt Edgar Link pending
0000950170-24-122318-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img200704480_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
srzn-20240930.htm Edgar Link pending
srzn-20240930.xsd Edgar Link pending
srzn-ex31_1.htm Edgar Link pending
srzn-ex31_2.htm Edgar Link pending
srzn-ex32_1.htm Edgar Link pending
srzn-ex32_2.htm Edgar Link pending
srzn-20240930_htm.xml Edgar Link completed